To the Editor The review by Dr Wells and colleagues1 on the treatment of venous thromboembolism requires some clarifications. Table 1 in the article summarized new oral anticoagulants as treatment options for venous thromboembolism. However, only rivaroxaban is currently approved in both the United States and Europe, dabigatran was recently approved by the US Food and Drug Administration (FDA), and apixaban awaits approval by both the FDA and the European Medicines Agency.
Bikdeli B. Therapies for Venous Thromboembolism. JAMA. 2014;311(24):2543. doi:10.1001/jama.2014.6114
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.